Eevia Health Plc, ("Eevia" or "The Company"), has received sales order from Taiwan of c. 13 KEUR for an organically certified bilberry extract.
The Taiwanese customer is an important and competitive distributor of ingredients and nutritional supplements in Taiwan. The distributor has a professional approach to quality and a strong presence in the market.
The sales value to Eevia of this new order is c. KEUR 13 EUR. The product is Eevia's branded ingredient Feno-Myrtillus® 25 Organic, which is a highly concentrated and organically certified bilberry extract with 25% anthocyanins.
There are 51 clinical studies with over 2000 subjects in peer-reviewed journals on anthocyanins from bilberries (Latin: Vaccinium Myrtillus - PubMed 2022). Fifteen studies (600 subjects) demonstrated positive metabolic health effects: reduction of glycemic response and improves blood sugar level, fatty acid and glucose metabolism, AND reduction of fatty acid accumulation in the liver.
Positive effects were also observed in eye health (8 positive clinical studies, 600 subjects), cardiovascular health (9 positive clinical studies with 600 subjects), digestive tract function, anti-oxidation, and chronic inflammation studies.
The order is expected to be followed by further repeat orders in the future.
For further information, please contact:
Stein Ulve, CEO, Eevia Health Plc
Email: stein.ulve@eeviahealth.com
Telephone: +358 400 22 5967
INFORMATION ABOUT EEVIA HEALTH PLC
Eevia Health Plc, founded in March 2017, addresses significant health problems with bioactive compounds extracted from plant materials. The materials are primarily wild harvested from the pristine Finnish and Swedish forests near or above the Arctic Circle. The extracts are sold B2B as ingredients in dietary supplements and food brands globally. These global brands utilize the ingredients in their consumer product formulas.
Eevia Health is a manufacturer of 100% organically certified plant extracts. Although a significant product, Elderberry extract, is made from cultivated berries, most of Eevia's other raw materials, such as bilberry, lingonberry, chaga-mushroom, and pine bark, are wild-harvested in a sustainable fashion.
Eevia Health operates a modern green-chemistry production facility in Finland. Manufacturing natural ingredients near the raw material harvest areas, Eevia offers a short value chain with an environmentally friendly carbon footprint, competitive pricing, and extreme transparency. Eevia listed its shares at Spotlight Stock Market in Sweden in June 2021, with the short name (ticker) EEVIA.
To learn more, please visit www.eeviahealth.com or follow Eevia Health on LinkedIn@EeviaHealth
Eevia Health ("Eevia" or "The Company") received a 13K USD /12KEUR sales order for the elderberry extract Feno-Sambucus™ 7 Organic.
Eevia Health Plc, ("Eevia" or "The Company"), has received a sales order from a European customer of c. 41 KEUR for an organically certified bilberry extract.
Eevia Health Plc ("Eevia" or "The Company") is releasing its quarterly financial report for the first quarter of 2023.
Eevia Health Plc ("Eevia" or "The Company") is promoting its products and value proposition by exhibiting at Vitafoods 2023, a key nutraceutical tradeshow in Geneva, Switzerland between 9 - 11 May 2023
Eevia Health Abp ("Eevia Health" or the "Company") has appointed Mangold Fondkommission to act as a liquidity provider for the company's shares. The assignment commences on Wednesday, May 4th, 2023.
Eevia Health Plc, ("Eevia" or "The Company"), has received a first sales order from a new customer in Germany of c. 11 KEUR for Feno-Myrtillus® 36 Organic, an organically certified bilberry extract
Eevia Health Plc ("Eevia" or "The Company") has decided to adjust the planned time for several financial events in 2023.
Eevia Health ("Eevia" or "The Company") received a 450 KSEK / 40 KEUR sales order for the Feno-Sambucus™ from its Australian distributor Ingredient Plus. The order is the second order from an Australian brand owner.
Due to a language setting choice in our Cision News portal with both English and Finnish chosen in the original press release, the press release did not go out automatically on all channels at the same time. To ensure the release is available on all channels, we re-release the press release. There are no changes to the substance of the release.
Eevia Health Plc, ("Eevia" or "The Company"), received several new sales orders totaling c. 23.8 MSEK / 2.1 MEUR from an International nutraceutical brand owner for an extract ingredient with immune health properties.
Eevia Health Plc, ("Eevia" or "The Company"), received several new sales orders totaling c. 23.8 MSEK / 2.1 MEUR from an International nutraceutical brand owner for an extract ingredient with immune health properties.